You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
兆科眼科(06622.HK)料首款仿制药最快明年商业化
阿思达克 04-29 15:49
兆科眼科(06622.HK)董事会主席兼行政总裁李小羿指,中国眼科药物市场未来十年将迎来高速增长时期,退化性黄斑病、乾眼症等病症治疗率低,预期拥有庞大发展空间。

公司预期2022年前推出三种仿制药,并计划未来三年提交九种仿制候选药物的简化新药申请。他透露,用於治疗青光眼的仿制药,新药申请预期於今年底可获批,最快明年商业化。

兆科去年度亏损7.26亿元人民币,首席财务官冯新彦预期仿制药商业化後将开始录得收入,但由於仿制药价格较低,相信要自主研发的创新药商业化後,财务水平才会出现根本性转折点。

是次上市引入新加坡政府投资公司、高瓴、TPG、奥博资本及爱尔眼科医院等基投,她表示,将探索在研发及商业化阶段的合作可能性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account